|Articles|April 15, 2002

BioPharm International

  • BioPharm International-04-01-2002
  • Volume 15
  • Issue 4

Beyond QSIT

by Joseph F. Noferi, Pharmacia GS API Biopharma and Daniel E. Worden If a process is out of control, an FDA inspector will find it, eventually. Companies that emerge as winners will be those that embrace compliance as a core business practice. Systems models provide strategic competitive advantage.
To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 24 years ago

Analytical Advances: Paperless or Less Paper?

almost 24 years ago

Outsourcing Outlook: Public CROs Craft New Strategies to Achieve Financial and Strategic Objectives

almost 24 years ago

Storing an Ion-Exchange Chromatography Gel in Dilute Alkali During Recycling Improves Cleaning

almost 24 years ago

Determining Protein Concentration, Part 1: Methodology

almost 24 years ago

Guest Editorial: The Protein Production Challenge

almost 24 years ago

Business Matters: Personalized Medicine or Blockbusterology?

almost 24 years ago

Advances in Amino Acid Analysis

almost 24 years ago

Analytical Advances: High-Throughput Purification System for Oligonucleotides Improves Synthetic Gene Production

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!